The charge was a result of the U.S. Justice Department’s investigation into Indivior’s branding of Suboxone Film, an opioid addiction treatment that contains opioids. The prosecution said Mr. Thaxter funneled misbranded drugs into interstate commerce by failing to prevent employees from providing misleading information to Massachusetts’ Medicaid program as it contemplated increasing its coverage for the treatment.
Mr. Thaxter, who will be sentenced Sept. 29, faces up to a year in prison and will pay $600,000 in fines and forfeitures. He announced he was stepping down from his role at Indivior June 29.
The plea comes after Indivior was charged with orchestrating a multibillion-dollar fraud scheme to increase prescriptions of Suboxone Film in April 2019.
More articles on opioids:
Screen all adults for unhealthy drug use, US task force advises
Walmart sued by shareholders for opioid distribution practices
Physicians, nurses and pharmacists among 19 indicted in multimillion-dollar opioid distribution ring
More articles on opioids:
Fentanyl found in most overdose cases at 2 Baltimore emergency departments, study finds
Screen all adults for unhealthy drug use, US task force advises
New York files fraud charges against Endo for misrepresenting opioids
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
